Suppr超能文献

大麻素 1 型受体阻断剂可改善严重失控型糖尿病大鼠肝脂肪浸润和炎症,并增加 Nrf2-AMPK 通路。

CB1 receptor blockade ameliorates hepatic fat infiltration and inflammation and increases Nrf2-AMPK pathway in a rat model of severely uncontrolled diabetes.

机构信息

Department of Nutritional Science and Food Management, Ewha Womans University, Seoul, Seoul, Republic of Korea.

Medical Research Institute, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.

出版信息

PLoS One. 2018 Oct 26;13(10):e0206152. doi: 10.1371/journal.pone.0206152. eCollection 2018.

Abstract

Previous studies have shown that the CB1 receptor antagonist reverses steatohepatitis and its related features of metabolic syndrome, such as obesity and type 2 diabetes. However, the beneficial effects of CB1 receptor blockade on hepatic steatosis and inflammation have not been investigated independently of its effects on body weight and glycemic control. At 32 weeks of age, OLETF rats were administered with rimonabant (10 mg·kg-1·day-1) by oral gavage for 6 weeks. No significant changes in body weight, OGTT, and serum glucose were observed in spite of rimonabant-decreased food intake. Moreover, there was a significant difference between initial and final body weight, regardless of rimonabant administration, indicating that OLETF rats were severely diabetic rats. Rimonabant administration significantly decreased serum liver enzyme levels such as ALT and AST, hepatic fat accumulation, lipid peroxidation, and cell death as demonstrated by the number of TUNEL-positive cells in severely uncontrolled diabetic OLETF rats. Significant decreases in hepatic gene expression of proinflammatory cytokines (CD11b, F4/80, MCP1, and TNFα), negative inflammatory mediators (SOCS1 and SOCS3), and fibrosis-related proteins (TGFβ, collagen 1, and TIMP1) were found in rimonabant-treated OLETF rats. Six-week administration of rimonabant significantly upregulated mRNA levels of CPT1α and PPARα related to β-oxidation. Moreover, significant increases in Nrf2 gene expression and its downstream genes, NQO1, GSAT, HO-1, and TXNRD1 along with increased AMPK phosphorylation were noted in uncontrolled diabetic rats treated with rimonabant. The observed potent inhibitory effects of CB1 receptor blockade on hepatic fat infiltration and cellular death in severely uncontrolled diabetic rats indicate that CB1 receptor is a possible therapeutic target. Increased Nrf2 and AMPK phosphorylation may play a role in the mechanism of rimonabant action.

摘要

先前的研究表明,CB1 受体拮抗剂可逆转脂肪性肝炎及其相关代谢综合征特征,如肥胖和 2 型糖尿病。然而,CB1 受体阻断对肝脂肪变性和炎症的有益影响尚未在不影响体重和血糖控制的情况下进行研究。在 32 周龄时,OLETF 大鼠通过口服灌胃给予利莫那班(10mg·kg-1·天-1)6 周。尽管利莫那班减少了食物摄入,但体重、OGTT 和血清葡萄糖没有明显变化。此外,无论是否给予利莫那班,初始体重和最终体重之间都有显著差异,表明 OLETF 大鼠是严重糖尿病大鼠。利莫那班给药可显著降低血清肝酶水平,如 ALT 和 AST,肝脂肪堆积,脂质过氧化和 TUNEL 阳性细胞数量表明严重失控的糖尿病 OLETF 大鼠的细胞死亡减少。在利莫那班治疗的 OLETF 大鼠中,肝脏促炎细胞因子(CD11b、F4/80、MCP1 和 TNFα)、负性炎症介质(SOCS1 和 SOCS3)和纤维化相关蛋白(TGFβ、胶原 1 和 TIMP1)的基因表达显著降低。利莫那班给药 6 周可显著上调与 β-氧化相关的 CPT1α 和 PPARα 的 mRNA 水平。此外,在未经治疗的糖尿病大鼠中,Nrf2 基因表达及其下游基因 NQO1、GSAT、HO-1 和 TXNRD1 的表达增加以及 AMPK 磷酸化增加。在严重失控的糖尿病大鼠中,CB1 受体阻断对肝脂肪浸润和细胞死亡的强烈抑制作用表明,CB1 受体可能是一个潜在的治疗靶点。增加的 Nrf2 和 AMPK 磷酸化可能在利莫那班作用的机制中发挥作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/092f/6203369/31c4682dd248/pone.0206152.g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验